Farther Finance Advisors, LLC
Position in CHRS — Coherus Oncology, Inc.
CIK 1992825
SAN FRANCISCO, CA
Position in CHRS
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$3,528
-$80 QoQ
Shares Held
2,520
+18.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#126
of 145 holders
Holding Since
Dec 2023
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in CHRS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Farther Finance Advisors, LLC holds $15,699,251 across 282 Biotechnology names. CHRS ranks #159 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
4,922 | $2,444,905 | |
| 2 | MRNA |
Moderna, Inc.
|
15,429 | $1,080,492 | |
| 3 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
12,088 | $985,292 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
11,241 | $879,833 | |
| 5 | EXEL |
Exelixis, Inc.
|
14,171 | $771,044 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,075 | $670,305 | |
| 7 | VKTX |
Viking Therapeutics, Inc.
|
15,171 | $591,820 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
7,871 | $450,378 |
All Filings in CHRS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,528 | 2,520 | Shares | Sole | 2026-07-17 | |
| 2026-03-31 | $3,608 | 2,135 | Shares | Sole | 2026-04-07 | |
| 2025-12-31 | $2,857 | 2,012 | Shares | Sole | 2026-01-23 | |
| 2025-03-31 | $37 | 47 | Shares | Sole | 2025-04-14 | |
| 2024-12-31 | $64 | 47 | Shares | Sole | 2025-02-10 | |
| 2024-03-31 | $217 | 91 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $9 | 3 | Shares | Sole | 2024-02-15 | |
| No filing history on record for this holder in this stock. | ||||||